Using Tissue Cell Culture To Make A Protein Or Polypeptide Patents (Class 435/70.1)
Fused or hybrid cells (Class 435/70.2)
Animal tissue cell culture (Class 435/70.3)
  • Genes with ES cell-specific expression
    Patent number: 8158766
    Abstract: The present invention relates to a probe for selecting ES cells, which characteristically contains one of DNAs having base sequences depicted in SEQ ID Nos; 1, 2, 3, 4, 5, 6, 7 and 8, or DNAs having base sequences depicted in SEQ ID Nos; 9, 11, 13, 15, 17, 19, 21, 23 and 41 and a screening method of ES cell using this probe. Preparation of a probe for selecting ES cells becomes feasible by identifying plural gene with ES cell-specific expressions (ECAT genes) and using the information of the base sequences of these gene groups. Efficient selection of ES cell enables supply of a large amount of ES cell expected to be applicable to regenerative medicine.
    Type: Grant
    Filed: July 10, 2006
    Date of Patent: April 17, 2012
    Assignees: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Shinya Yamanaka, Eiko Kaiho
  • Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
    Patent number: 8153397
    Abstract: The present invention relates to the construction, expression, and purification of synthetic or recombinant light chain (LC) botulinum neurotoxin genes from all botulinum neurotoxin serotypes. The methods of the invention can provide 1.1 g of the LC per liter of culture. The LC product is stable and proteolytically active. Methods of using the products of the invention are described.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: April 10, 2012
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Leonard A. Smith, Melody Jensen
  • ligand (thrombopoietin), nucleic acids encoding such, and methods of treatment using ligand
    Patent number: 8147844
    Abstract: Isolated thrombopoietin (TPO), isolated DNA encoding TPO, and recombinant or synthetic methods of preparing and purifying TPO are disclosed. Various forms of TPO are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and megakaryocyte progenitor cells. Accordingly, these compounds may be used for treatment of thrombocytopenia.
    Type: Grant
    Filed: December 28, 1994
    Date of Patent: April 3, 2012
    Assignee: Genentech, Inc.
    Inventors: Dan L. Eaton, Frederic J. de Sauvage
  • Cell culture carrier comprising poly(meth)acrylic (salt) particle and artificial polypeptide
    Patent number: 8148111
    Abstract: A carrier for cell culture is provided which improves the cell proliferativity in serum-free culture and which is free from risk from infection factor contamination. The gist of the features of the present invention is to be formed of a crosslinked poly(meth)acrylic acid (salt) particle (A) and an artificial polypeptide (P) having at least one cell-adhesive minimal amino acid sequence (X) in one molecule and to have a water retention value of from 2 to 50 g/g. The (A) is preferably a particle produced by reversed phase suspension polymerization of an aqueous monomer solution containing (meth)acrylic acid and/or an alkali metal salt of (meth)acrylic acid. The (P) preferably has at least one auxiliary amino acid sequence (Y) in one molecule of the (P). The (X) is preferably an Arg Gly Asp sequence.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: April 3, 2012
    Assignee: Sanyo Chemical Industries, Ltd.
    Inventors: Masato Kurokawa, Kazuhiro Takahashi
  • Interferon-like proteins and uses thereof
    Patent number: 8148109
    Abstract: The present invention provides Interferon-Like (IFN-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing IFN-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IFN-L polypeptides.
    Type: Grant
    Filed: August 8, 2005
    Date of Patent: April 3, 2012
    Assignee: Amgen Inc.
    Inventors: Andrew Welcher, Duanzhi Wen, Michael Kelley
  • AXMI-031, AXMI-039, AXMI-040 and AXMI-049, a family of novel delta-endotoxin genes and methods for their use
    Patent number: 8147856
    Abstract: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed, and antibodies specifically binding to those amino acid sequences.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: April 3, 2012
    Assignee: Athenix Corp.
    Inventors: Nadine Carozzi, Nicholas Duck, Theodore Kahn, Nalini Desai, Shruti Agarwal, Daniel John Tomso, Rong Guo, Julia Daum
  • Systems and methods for clonal expression in plants
    Patent number: 8148608
    Abstract: The present invention provides systems and methods for generating clonal root lines, clonal root cell lines, clonal plant cell lines, and clonal plants and for expressing gene products in such cell lines and plants. In some embodiments, a viral vector containing a polynucleotide of interest operably linked to a promoter is introduced into a plant or portion thereof to generate clonal root lines, clonal root cell lines, clonal plant cell lines, and clonal plants. According to certain inventive methods, a viral vector containing a polynucleotide of interest operably linked to a promoter is introduced into cells of a plant cell line that is maintained in culture to generate clonal plant cell lines and clonal plants. The invention provides clonal root lines, clonal root cell lines, clonal plant cell lines, and clonal plants generated using inventive methods.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: April 3, 2012
    Assignee: Fraunhofer USA, Inc
    Inventors: Vidadi Yusibov, Marina Skarjinskaia
  • Nucleic acid encoding TNFx protein
    Patent number: 8148507
    Abstract: Nucleic acids encoding mammalian, e.g., primate or rodent, genes, purified proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: April 3, 2012
    Assignee: Schering Corporation
    Inventors: Christi L. Parham, Daniel M. Gorman, Hirokazu Kurata, Naoko Arai, Theodore R. Sana, Jeanine D. Mattson, Erin E. Murphy, Chetan Savkoor, Jeffery Grein, Kathleen M. Smith, Terrill K. McClanahan
  • R-ALPHA1 antitrypsin anion exchange chromatography
    Patent number: 8148502
    Abstract: The present invention relates to a method for obtaining highly purified recombinant alpha1-antitrypsin (rAAT) using anion exchange chromatography, wherein a composition comprising rAAT and at least one impurity originating from cultivation of cells used for generating of rAAT is loaded onto a column containing anion exchange material and the anion exchange chromatography is carried out with buffers containing phosphate ions and N-acetylcysteine.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: April 3, 2012
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Artur Mitterer, Meinhard Hasslacher, Christian Fiedler
  • Norovirus and Sapovirus antigens
    Patent number: 8142793
    Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: March 27, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
  • Method of making a plasminogen activator polypeptide with clot-specific streptokinase activity
    Patent number: 8143027
    Abstract: The present invention provides polynucleotides encoding clot-specific streptokinase proteins possessing altered plasminogen characteristics, including enhanced fibrin selectivity. The kinetics of plasminogen activation by these proteins are distinct from those of natural streptokinase, in that there is a temporary delay or lag in the initial rate of catalytic conversion of plasminogen to plasmin. Also disclosed are processes for preparing the proteins.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: March 27, 2012
    Assignee: Council of Scientific & Industrial Research of Rafi Marg
    Inventors: Girish Sahni, Rajesh Kumar, Chiati Roy, Kammara Rajagopal, Deepak Nihalani, Vasudha Sundaram, Mahavir Yadav
  • Mammalian expression vector pUHAB
    Patent number: 8137933
    Abstract: The present invention relates to the construction and utilization of a new mammalian expression vector that contains a unique multiple cloning site (MCS), designated pUHAB. The pUHAB vector comprises a high copy replication origin (ColE1), a drug resistance gene (TK-Hygromycin), and a human cytomegalovirus promoter operably associated with a unique intron (hCMV/intron). Further, pUHAB comprises a selectable marker conferring resistance to kanamycin in bacterial cells, and a phage f1(+) region. pUHAB can be used to transiently or stably express cloned genes when transfected into mammalian cells. The invention also encompasses kits and host cells and cell lines comprising pUHAB, and methods of producing a recombinant protein using pUHAB.
    Type: Grant
    Filed: November 12, 2009
    Date of Patent: March 20, 2012
    Assignee: Schering Corporation
    Inventor: Deba P. Saha
  • Minimal DNA sequence acting as a chromatin insulator and its use in protein expression
    Patent number: 8133699
    Abstract: The invention relates to expression vectors comprising a DNA sequence of 146 bp capable of acting as chromatin insulator, to host cells containing such vectors, to a method of producing a desired polypeptide by using vectors containing said sequence and to the use of said DNA sequence.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: March 13, 2012
    Assignee: Merk Serono S.A.
    Inventors: Philippe Chatellard, Markus Imhof
  • Agonistic binding molecules to the human OX40 receptor
    Patent number: 8133983
    Abstract: The present invention provides binding molecules, such as human binding molecules, that bind to and stimulate the human OX40-receptor. The invention also provides nucleic acids encoding such binding molecules. Methods for producing such binding molecules are also provided by the present invention. The binding molecules and nucleic acids are useful in the stimulation of human T-cells and can be used to enhance antigen-specific immune responses.
    Type: Grant
    Filed: March 23, 2009
    Date of Patent: March 13, 2012
    Assignee: Crucell Holland B.V.
    Inventors: Alexander Berthold Hendrik Bakker, Pauline Marie Louise Meester-Rood, Adrianus Quirinus Bakker
  • gene with lepidopteran activity
    Patent number: 8129594
    Abstract: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, especially plant pests.
    Type: Grant
    Filed: June 3, 2009
    Date of Patent: March 6, 2012
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Andre R. Abad, Hua Dong, Sue B. Lo, Xiaomei Shi
  • Norovirus and sapovirus antigens
    Patent number: 8124104
    Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: February 28, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc
    Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
  • Method of producing TAT-HOXB4H
    Patent number: 8124377
    Abstract: The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: February 28, 2012
    Assignee: Taiwan Advance Bio-Pharm Inc.
    Inventors: Kou-Juey Wu, Chi-Hung Huang
  • Method of producing recombinant protein
    Patent number: 8124374
    Abstract: An object of the present invention is to provide a method of mass-producing recombinant protein by the liquid culture method with koji molds as host. According to the present invention, it is provided a method of producing recombinant protein by using the recombinant koji molds which are obtained by transforming koji molds as host comprising: culturing the recombinant koji molds in a liquid medium which contains as culture raw material at least one selected from the group consisting of the cereal of which surface is entirely or partly covered with at least husks, the bean and/or the tuber of which surface is covered with hulls and the amaranthus and/or the quinoa without pre-treatment such as grinding or crushing; and collecting the recombinant protein from the culture product.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: February 28, 2012
    Assignee: Asahi Breweries, Ltd.
    Inventors: Hiroshi Shoji, Toshikazu Sugimoto
  • Recombinant adenoviral vectors and applications thereof
    Patent number: 8119396
    Abstract: Recombinant adenoviruses or pseudoviruses having a deletion of all or part of the region of the adenovirus genome corresponding to nucleotides 311 to 499 in canine adenovirus type 2 (GeneBank J04368). Therapeutic methods of using the recombinant adenovirus or pseudovirus.
    Type: Grant
    Filed: October 8, 2003
    Date of Patent: February 21, 2012
    Assignees: Institut National de la Recherche Agronomique (INRA), Ecole Nationale Veterinaire d'Alfort
    Inventors: Marc Eloit, Bernard Klonjkowski
  • Antennapedia-dominant negative mastermind-like construct
    Patent number: 8119366
    Abstract: The present invention is based on the discovery that the Notch signaling pathway is associated with cancer. Accordingly, the invention provides methods and compositions for treating cancer. Also provided are methods of modulating the expression and/or activity of proteins in the Notch signaling pathway for use in diagnoses and treatment of cancer in a subject.
    Type: Grant
    Filed: October 3, 2008
    Date of Patent: February 21, 2012
    Assignee: Trojan Technologies, Ltd.
    Inventor: Spyros Stylianou
  • Methods for producing norovirus VLPS
    Patent number: 8119145
    Abstract: Immunogenic compositions that elicit immune responses against Norovirus and Sapovirus antigens are described. In particular, the invention relates to polynucleotides encoding one or more capsid proteins or other immunogenic viral polypeptides from one or more strains of Norovirus and/or Sapovirus, coexpression of such immunogenic viral polypeptides with adjuvants, and methods of using the polynucleotides in applications including immunization and production of immunogenic viral polypeptides and viral-like particles (VLPs). Methods for producing Norovirus- or Sapovirus-derived multiple epitope fusion antigens or polyproteins and immunogenic compositions comprising one or more immunogenic polypeptides, polynucleotides, VLPs, and/or adjuvants are also described.
    Type: Grant
    Filed: March 24, 2009
    Date of Patent: February 21, 2012
    Assignee: Novartis Vaccines & Diagnostics, Inc.
    Inventors: Doris Coit, Michael Houghton, Colin McCoin, Angelica Medina-Selby, Michael Vajdy
  • gene with coleopteran activity
    Patent number: 8115063
    Abstract: The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of Bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including Coleoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, DNA constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments. These compositions find use in methods for controlling pests, especially plant pests.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: February 14, 2012
    Assignee: Pioneer Hi-Bred International, Inc.
    Inventors: Andre R. Abad, Hua Dong, Sue B. Lo, Xiaomei Shi
  • In vivo incorporation of unnatural amino acids
    Patent number: 8114648
    Abstract: The invention provides methods and compositions for in vivo incorporation of unnatural amino acids. Also provided are compositions including proteins with unnatural amino acids.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: February 14, 2012
    Assignees: The Scripps Research Institute, The Regents of the University of California
    Inventors: Peter G. Schultz, Lei Wang, John Christopher Anderson, Jason W. Chin, David R. Liu, Thomas J. Magliery, Eric L. Meggers, Ryan Aaron Mehl, Miro Pastrnak, Stephen William Santoro, Zhiwen Zhang
  • Method for producing temperature sensitive influenza A viruses
    Patent number: 8114415
    Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: February 14, 2012
    Assignee: Medimmune, LLC
    Inventors: Erich Hoffmann, Hong Jin, Bin Lu, Gregory Duke, George Kemble, Zhongying Chen
  • Modified interferon beta polypeptides and their uses
    Patent number: 8114630
    Abstract: Modified interferon beta polypeptides and uses thereof are provided.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: February 14, 2012
    Assignee: Ambrx, Inc.
    Inventors: Vadim Kraynov, Nick Knudsen, Anna-Maria A. Hays Putnam, Denise Krawitz, Jason Pinkstaff, Heather Myler
  • METHOD FOR GENERATING HYPOALLERGENIC GLYCOPROTEINS IN MUTATED OR TRANSGENIC PLANTS OR PLANT CELLS, AND MUTATED OR TRANSGENIC PLANTS AND PLANT CELLS FOR GENERATING HYPOALLERGENIC GLYCOPROTEINS
    Publication number: 20120036600
    Abstract: Method for providing a hypoallergenic glycoprotein includes growing at least one of a mutated plant, a part of the mutated plant, plant cells produced from the mutated plant, a transgenic plant, a part of the transgenic plant and plant cells produced from the transgenic plant wherein an activity of an enzyme Golgi ?-mannosidase II has been eliminated or decreased so as to obtain a grown material. The hypoallergenic glycoprotein is isolated from the grown material.
    Type: Application
    Filed: April 25, 2009
    Publication date: February 9, 2012
    Applicant: WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
    Inventors: Antje Von Schaewen, Heidi Kaulfuerst-Soboll
  • Nucleic acids encoding DCRS5
    Patent number: 8110378
    Abstract: Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: February 7, 2012
    Assignee: Schering Corporation
    Inventors: Madaline Chirica, Robert A. Kastelein, Kevin W. Moore, Christi L. Parham
  • Targeted integration into the PPP1R12C locus
    Patent number: 8110379
    Abstract: Disclosed herein are methods and compositions for targeted integration of an exogenous sequence into the human PPP1R12C locus, for example, for expression of a polypeptide of interest.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: February 7, 2012
    Assignee: Sangamo Biosciences, Inc.
    Inventors: Russell DeKelver, Philip D. Gregory, David Paschon, Phillip Tam, Fyodor Urnov
  • Long-acting EPO polypeptides and derivatives thereof and methods thereof
    Patent number: 8110376
    Abstract: A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to an EPO peptide are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: February 7, 2012
    Assignee: Prolor Biotech Ltd.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Human interferon-beta mutein
    Patent number: 8101716
    Abstract: The present invention relates to a human interferon-beta mutein. In particular, the present invention relates to the human interferon-beta mutein having one or two additional sugar chains compared to natural human interferon-beta.
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: January 24, 2012
    Inventors: Young Kee Shin, Moon Kyoung So, Jong Min Lee, Ji-Hye Yang, Ji Uk Yoo, Tae Ho Byun, Ji Tai Kim, Han Kyu Oh, Ho CHul Yoon, Ji Soo Ahn, Kyung Song, Jae Ho Jin
  • Polynucleotides encoding long-acting growth hormone polypeptides and methods of producing same
    Patent number: 8097435
    Abstract: A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a peptide-of-interest are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed.
    Type: Grant
    Filed: March 11, 2009
    Date of Patent: January 17, 2012
    Assignee: Prolor Biotech Ltd.
    Inventors: Fuad Fares, Udi Eyal Fima
  • Cancer vaccines and vaccination methods
    Patent number: 8097256
    Abstract: Methods and compositions for treating cancers (e.g., neural cancers) by dendritic cell vaccination are provided herein.
    Type: Grant
    Filed: September 28, 2007
    Date of Patent: January 17, 2012
    Assignee: Cedars-Sinai Medical Center
    Inventors: John S. Yu, Gentao Liu, Keith L. Black
  • Modified leukocyte Ig-like receptor family members (LIRs) with increased affinity for class 1 MHC and their uses in modulating T-cell activation
    Patent number: 8092807
    Abstract: The present invention provides polypeptides having the property of binding to a given Class I pMHC CHARACTERISED IN THAT said polypeptide has a KD for the said given Class I pMHC of less than or equal to 1 ?M and/or has an off-rate (koff) for the said given Class I pMHC molecule of 2 S?1 or slower AND said polypeptide has at least a 45% identity and/or 55% similarity to a defined high-affinity ILT-like molecule AND said polypeptide inhibits CD8 binding to the given pMHC to a greater extent than a soluble truncated variant of Wild-Type ILT-2. Such high-affinity ILT-like molecules are useful, either alone or associated with a therapeutic agent, for the inhibition of cytotoxic T cell (CTL) responses.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: January 10, 2012
    Assignee: MediGene AG
    Inventors: Bent Karsten Jakobsen, Yi Li, Ruth Karen Moysey
  • Serum-free culture medium for the production of recombinant gonadotropins
    Patent number: 8093052
    Abstract: The present invention is in the field of the manufacture of recombinant proteins. More specifically, it relates to the use of a serum-free culture medium comprising an antioxidant for the production of recombinant dimeric gonadotropins. The antioxidant may be selected from the group consisting of L-glutathione, 2-mercaptoethanol, L-methionine and a combination of ascorbic acid and of (+)-alpha-tocoplierol.
    Type: Grant
    Filed: July 4, 2006
    Date of Patent: January 10, 2012
    Assignee: Ares Trading S.A.
    Inventors: Jean-Pierre Fonta, Paul Ducommun, Véronique Deparis
  • Preparation of a therapeutic composition
    Patent number: 8084239
    Abstract: Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 mn/280 nm and 1.359 at 260 nm/230 nm.
    Type: Grant
    Filed: April 27, 2009
    Date of Patent: December 27, 2011
    Assignee: Ohr Pharmaceuticals, Inc
    Inventors: Shalom Z. Hirschman, Irach B. Taraporewala
  • Recombinant cell clones having increased stability and methods of making and using the same
    Patent number: 8084252
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Grant
    Filed: August 2, 2010
    Date of Patent: December 27, 2011
    Assignee: Baxter Innovations GmbH
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Nogo-B receptor antagonists
    Patent number: 8084228
    Abstract: Nogo-B receptors bind to Nogo-B and mediate its biological function. We have discovered that Nogo-B receptor is a component of endothelial cells, and is highly expressed in intact blood vessels. The present invention provides compositions comprising the Nogo-B receptor and fragments and fusion proteins thereof. The present invention also relates to nucleic acids encoding the Nogo-B receptor and fragments and fusion proteins thereof, as well as vectors and cells comprising such nucleic acids. The present invention also relates to antibodies specific for the Nogo-B receptor and fragments and fusion proteins thereof. The present invention also provides methods for preventing, detecting and treating Nogo-B receptor-related diseases, disorders and conditions.
    Type: Grant
    Filed: January 12, 2007
    Date of Patent: December 27, 2011
    Assignee: Yale University
    Inventors: William C. Sessa, Quing Miao
  • Recombinant cell clones having increased stability and methods of making and using the same
    Patent number: 8084251
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Grant
    Filed: May 12, 2010
    Date of Patent: December 27, 2011
    Assignee: Baxter Innovations GmbH
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Method for preparing soluble and active recombinant proteins usins PDI as a fusion partner
    Patent number: 8080387
    Abstract: The present invention relates to a method for producing a recombinant protein capable of increasing expression rate of a target protein and also improving solubility and folding of the expressed target protein using a modified protein disulfide isomerase (PDI) as a fusion partner, and an expression vector containing the modified PDI gene as a fusion partner. The method for preparing a recombinant protein using a modified PDI as a fusion partner according to the present invention may solve the problems concerning a low yield and solubility and folding that conventional fusion partners have, and be widely used for protein drug and industrial protein production.
    Type: Grant
    Filed: October 24, 2005
    Date of Patent: December 20, 2011
    Assignee: Vexxon, Inc.
    Inventors: Hang-Cheol Shin, Yean-Hee Park, Hyang-Do Song, Eung-Yoon Kim, Ha-A-Rin Chon, Hye-Ran Hyun
  • Recombinant cell clones having increased stability and methods of making and using the same
    Patent number: 8080414
    Abstract: Disclosed are a stable recombinant cell clones which are stable in serum- and protein-free medium for at least 40 generations, a biomass obtained by multiplying the stable cell clone under serum- and protein-free culturing conditions, and a method of preparing recombinant proteins by means of the biomass. Furthermore, the invention relates to a method of recovering stable recombinant cell clones.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: December 20, 2011
    Assignee: Baxter Innovations GmbH
    Inventors: Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • MACROLACTONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF FOR THE TREATMENT OF CANCER
    Publication number: 20110306563
    Abstract: The present invention relates to the use of a compound of the formula (I), wherein X and Y independently of one another are OH, O—(C1-C6)-alkyl, NH2 or NH—(C1-C6)-alkyl, or X and Y together form a group —O— or wherein X and Y together form a further bond between the C atoms to which they are attached; R1 and R2 independently of one another are H, Cl or Br; R3 is H,(C1-C6)alkyl, C(?O)—(C1-C6)-alkyl or (C1-C6)-alkylene-NH—(C1-C6)-alkyl; R4 is H, (C1-C6)-alkyl or C(?O)—(C1-C6)-alkyl, and R5 is methyl or ethyl; or a physiologically tolerable salt of a compound of the formula (I), for the treatment and/or prophylaxis of cancer diseases, a pharmaceutical composition for the treatment and/or prophylaxis of cancer diseases comprising a compound of the formula (I), a compound of the formula (I) and a process for the preparation of the compound (I).
    Type: Application
    Filed: December 10, 2009
    Publication date: December 15, 2011
    Applicant: SANOFI
    Inventors: Holger Hoffmann, Michael Caspers, Dietmar Schummer, Herbert Kogler, Christine Klemke-Jahn
  • Polynucleotides encoding rod-derived cone viability factor (rdcvf) and methods of using the same
    Patent number: 8071745
    Abstract: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of retinal dystrophy, age-related macular degeneration, Bardet-Biedel syndrome, Bassen-kornzweig syndrome, best disease, choroidema, gyrate atrophy, congenital amourosis, refsun syndrome, stargardt disease and Usher syndrome. In particular, the invention relates to a protein, termed “Rdcvf1,” that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with non-sufferers, antibodies which recognize this protein, and methods for diagnosing such conditions.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: December 6, 2011
    Assignees: Novartis AG, Universite de Strasbourg
    Inventors: Thierry Léveillard, José Alain Sahel, Saddek Mohand-Said, David Hicks
  • Nucleic acid molecules encodng a cathepsin L-like cysteine protease
    Patent number: 8071736
    Abstract: Compositions and methods for protecting a plant from an insect pest are provided. In particular, nucleic acid sequences encoding insect protoxins modified to comprise at least one proteolytic activation site that is sensitive to a plant protease or an insect gut protease are provided. Cleavage of the modified protoxin at the proteolytic activation site by a protease produces an active insect toxin. Methods of using the modified insect protoxin nucleic acid sequences and the polypeptides they encode to protect a plant from an insect pest are provided. Particular embodiments of the invention further provide modified insect protoxin compositions and formulations, expression cassettes, and transformed plants, plant cells, and seeds.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: December 6, 2011
    Assignees: Pioneer Hi-Bred International, Inc., E.I. Dupont de Nemours and Company
    Inventors: Andre R. Abad, Ronald D. Flannagan, Rafael Herrmann, Albert L. Lu, Billy F. McCutchen, James K. Presnail, Janet A. Rice, James F. Wong, Cao-Guo Yu
  • Thermophilic and thermoacidophilic sugar transporter genes and enzymes from and related organisms, methods
    Patent number: 8071748
    Abstract: Isolated and/or purified polypeptides and nucleic acid sequences encoding polypeptides from Alicyclobacillus acidocaldarius are provided. Further provided are methods for transporting sugars across cell membranes using isolated and/or purified polypeptides and nucleic acid sequences from Alicyclobacillus acidocaldarius.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: December 6, 2011
    Assignee: Battelle Energy Alliance, LLC
    Inventors: David N. Thompson, William A. Apel, Vicki S. Thompson, David W. Reed, Jeffrey A. Lacey
  • Humanized anti-IL-6 antibodies
    Patent number: 8062866
    Abstract: The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: November 22, 2011
    Assignee: Femta Pharmaceuticals, Inc.
    Inventors: Gerhard Frey, Hwai Wen Chang, Jay Short
  • Fusion partner for production of monoclonal rabbit antibodies
    Patent number: 8062867
    Abstract: The invention provides a rabbit-derived immortal B-lymphocyte capable of fusion with a rabbit splenocyte to produce a hybrid cell that produces an antibody. The immortal B-lymphocyte does not detectably express endogenous immunoglobulin heavy chain and may contain, in certain embodiments, an altered immunoglobulin heavy chain-encoding gene. A hybridoma resulting from fusion between the subject immortal B-lymphocyte and a rabbit antibody-producing cell is provided, as is a method of using that hybridoma to produce an antibody. The subject invention finds use in a variety of different diagnostic, therapeutic and research applications.
    Type: Grant
    Filed: April 6, 2010
    Date of Patent: November 22, 2011
    Assignee: Epitomics, Inc.
    Inventors: Robert Pytela, Weimin Zhu, Yaohuang Ke, Qi Qian, Harry C. Au
  • PLANTS AND SEEDS OF CORN VARIETY CV458809
    Publication number: 20110283384
    Abstract: According to the invention, there is provided seed and plants of the corn variety designated CV458809. The invention thus relates to the plants, seeds and tissue cultures of the variety CV458809, and to methods for producing a corn plant produced by crossing a corn plant of variety CV458809 with itself or with another corn plant, such as a plant of another variety. The invention further relates to corn seeds and plants produced by crossing plants of variety CV458809 with plants of another variety, such as another inbred line. The invention further relates to the inbred and hybrid genetic complements of plants of variety CV458809.
    Type: Application
    Filed: May 11, 2010
    Publication date: November 17, 2011
    Inventor: Lance Veldboom
  • Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
    Patent number: 8058027
    Abstract: The invention relates to cell culture methods, kits and cell lines for producing recombinant products, e.g. therapeutic proteins and antibodies, in the presence of reduced levels of one or more contaminants and further to methods of purifying those products.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: November 15, 2011
    Assignee: Millipore Corporation
    Inventor: Anthony DiLeo
  • Viruses comprising mutant ion channel protein
    Patent number: 8057806
    Abstract: A method to prepare viruses lacking ion channel activity is provided.
    Type: Grant
    Filed: January 26, 2005
    Date of Patent: November 15, 2011
    Assignee: Wisconsin Alumni Research Foundation
    Inventor: Yoshihiro Kawaoka
  • Stabilization and blueing of anthocyanin pigments using gene encoding aromatic acyltransferase capable of transferring an aromatic acyl group to the 3?-position of anthocyanin
    Patent number: 8053634
    Abstract: A method of acylating the 3? position of anthocyanin using an enzyme that transfers an aromatic acyl group to a sugar at the 3? position of anthocyanin or a gene encoding the enzyme.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: November 8, 2011
    Assignee: Suntory Holdings Limited
    Inventors: Yoshikazu Tanaka, Yukihisa Katsumoto, Masako Mizutani, Yuko Fukui, Junichi Togami